Oxford Cannabinoid Technologies Holdings PLC OCTHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.04
- Day Range
- $0.00–0.04
- 52-Week Range
- $0.00–0.04
- Bid/Ask
- $0.00 / $0.04
- Market Cap
- $3.05 Mil
- Volume/Avg
- 45,110 / 29,128
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.oxcantech.com
Valuation
|
Metric
|
OCTHF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.57 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OCTHF
|
|---|---|
Quick Ratio | 3.32 |
Current Ratio | 3.32 |
Interest Coverage | — |
Quick Ratio
OCTHF
Profitability
|
Metric
|
OCTHF
|
|---|---|
Return on Assets (Normalized) | −85.30% |
Return on Equity (Normalized) | −168.85% |
Return on Invested Capital (Normalized) | −104.78% |
Return on Assets
OCTHF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Dsgdgvhbc | Vvxgq | $635.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cxnpmxdv | Qbqqp | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ckkqlqjn | Khrkrs | $114.2 Bil | |||
| Moderna Inc
MRNA
| Nqxwhyxk | Vlqq | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Vzpncwg | Svbhm | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Nfnbdbyd | Gcwh | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sysjbdd | Kzwhkbc | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yxxqwbvwg | Yfgrfy | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Vbqjcmw | Slwl | $12.8 Bil | |||
| Incyte Corp
INCY
| Drkyjmlr | Fkvfw | $12.2 Bil |